MiNK Therapeutics, Inc.
NASDAQ:INKT
0.729 (USD) • At close November 4, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Revenue
| 0 | 2,704.743 | 0 | 0 | 0.69 |
| Cost of Revenue
| 0.205 | 30,949.278 | 28,358.591 | 0.055 | 0 |
| Gross Profit
| -0.205 | -28,244.535 | -28,358.591 | -0.055 | 0.69 |
| Gross Profit Ratio
| 0 | -10.443 | 0 | 0 | 1 |
| Reseach & Development Expenses
| 15.49 | 23.115 | 13.966 | 9.509 | 19.654 |
| General & Administrative Expenses
| 7.431 | 7.834 | 4.64 | 1.288 | 3.828 |
| Selling & Marketing Expenses
| -7,423.882 | 0 | 0 | 0 | 0 |
| SG&A
| 7.431 | 7.834 | 4.64 | 1.288 | 3.828 |
| Other Expenses
| -0 | 2.705 | -9.53 | -3.001 | 0.551 |
| Operating Expenses
| 22.921 | 30.949 | 18.606 | 10.797 | 23.482 |
| Operating Income
| -22.921 | -30.949 | -28.359 | -14.637 | -22.284 |
| Operating Income Ratio
| 0 | -0.011 | 0 | 0 | -32.314 |
| Total Other Income Expenses Net
| 0.463 | 2.958 | -1.854 | -1.602 | -1.518 |
| Income Before Tax
| -22.458 | -27.991 | -30.213 | -16.239 | -23.802 |
| Income Before Tax Ratio
| 0 | -0.01 | 0 | 0 | -34.515 |
| Income Tax Expense
| 0 | -3.211 | -7.099 | -0.56 | 2.112 |
| Net Income
| -22.458 | -24.78 | -23.114 | -15.679 | -25.914 |
| Net Income Ratio
| 0 | -0.009 | 0 | 0 | -37.577 |
| EPS
| -0.65 | -0.74 | -0.69 | -0.47 | -0.78 |
| EPS Diluted
| -0.65 | -0.74 | -0.69 | -0.47 | -0.78 |
| EBITDA
| -22.716 | -30.828 | -28.059 | -13.743 | -22.204 |
| EBITDA Ratio
| 0 | -0.011 | 0 | 0 | -32.198 |